ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: While the currently available tyrosine kinase inhibitors (TKIs) for the chronic phase of Philadelphia chromosome-positive chronic myeloid leukemia (CML) enable a highly effective treatment control of the disease, BCR::ABL1 single nucleotide variants (BSNVs) pose a real challenge for a great proportion of patients.